Ad26 EBOV vaccine(Crucell Holdings, Inc.)

Sander van Deventer is co-founder and former Chief Technology Officer of the Company Elena Ritsou assumes role of Chief Corporate Officer Barbara Sanders is promoted to Chief Technology Officer Industry veteran Frank Walsh joins as an Independent Board Member AMSTERDAM--(BUSINESS WIRE)-- VectorY Therapeutics, a biotech company developing innovative vectorized antibody approaches for the treatment of neurodegenerative diseases, today announces the appointment of Sander van Deventer, co-founder and formerly Chief Technology Officer, as Chief Executive Officer. The Company has also made key appointments to its leadership team. Sander van Deventer has 25 years of experience in drug development and a longstanding track record in antibody and gene therapy development. He succeeds Alexander Vos, who led the Company during the start-up phase. “I’m delighted to welcome Sander as our new CEO,” said Carlo Incerti, MD, Chair of the Supervisory Board at VectorY. “We are confident that with his impressive industry track record and scientific knowledge, Sander will lead VectorY forward at this exciting time as we work towards our first IND. I would also like to thank Alexander for his commitment and contribution to VectorY and wish him all the best in his future endeavors.” “In the two years since VectorY’s inception, we have made significant progress in validating our technology and are now advancing towards development,” said Sander van Deventer, Chief Executive Officer of VectorY. “We have a promising technology of vectorized antibodies which has the potential to transform the therapeutic landscape in neurodegenerative diseases, such as Amyotrophic Lateral Sclerosis (ALS), Huntington’s and ultimately dementias. I am looking forward to working with the team to progress our innovative pipeline towards our first IND.” Other VectorY appointments Elena Ritsou joins as Chief Corporate Officer (CCO), a newly created role in which she will lead Business Development and Strategy, Intellectual Property, Legal, Human Resources and Communications. Barbara Sanders is promoted to the position of Chief Technology Officer (CTO), having served as Vice President Vector Development since the Company’s inception. Frank Walsh joins as an Independent Board Member. He brings two decades of experience as a senior executive in pharma and biotech companies as well as invaluable research experience in ALS, where his current work concentrates on the role of the neurotrophin receptor TrkB on motor neuron survival. Sander van Deventer concluded: “We welcome Elena Ritsou as Chief Corporate Officer and Frank Wash as an independent board member and congratulate Barbara Sanders on her new role as Chief Technology Officer. With these valuable additions to the leadership team, VectorY will be in an even stronger position to progress its pioneering work of vectorized antibodies to tackle devastating diseases such as ALS and Huntington’s disease.” -Ends- Notes to Editors Full biographies Sander van Deventer, MD, PhD – Chief Executive Officer Sander is a co-founder of VectorY and has 25 years of experience in drug development. He had a critical role in the development of the first commercial monoclonal antibody (Remicade) and the first gene therapy to be granted market authorization in the Western world (Glybera). Sander is also co-founder of Forbion, a leading life science venture capital firm where he is currently an Operating Partner. In 1998 he co-founded Amsterdam Molecular Therapeutics (AMT N.V.), currently uniQure N.V. (NASDAQ: QURE), an AAV-based gene therapy company, acting subsequently as CSO, CMO and CEO. He also served as CEO of Dezima. In 2017, he re-joined uniQure as its part-time CSO where he brought the hemophilia B and Huntington’s disease programs to clinical development. Sander is a former professor of Experimental Medicine and Gastroenterology at the Amsterdam Academic Medical Center and of Translational Gastroenterology at the University of Leiden. He authored over 80 book chapters, 600 peer-reviewed papers, organized international scientific conferences, and supervised more than 40 PhD students. He served on the boards of Hookipa, Engene, Borean, Dezima, Argos, and the scientific advisory boards of Hookipa, Argos, Engene and Staten. Elena Ritsou, PhD – Chief Corporate Officer Elena joins VectorY as the Chief Corporate Officer as well as BioGeneration Ventures as a Venture Partner. She brings 20 years of experience in Corporate and Business Development in pharmaceutical and biotech companies, most recently as the Chief Business Officer of Gamma Delta Therapeutics leading its acquisition by Takeda in Q2 2022. Prior to Gamma Delta Elena was Global Head Oncology Business Development at Ipsen Pharma where she was instrumental on late and early-stage transactions and acquisitions. Earlier in her career she held Business Development roles of increasing responsibility at Sanofi and Genzyme. Elena holds a BSc in Immunology from the University of Edinburgh, UK, a PhD in Tumor Immunology from the German Cancer Research Centre, Heidelberg, Germany and a MSc in Finance from HEC Business School, Paris, France. Barbara Sanders, PhD – Chief Technology Officer Barbara is a co-founder of VectorY and has served as Vice President Vector Development since the Company’s inception in 2020. She has over 10 years of experience in viral vector development within large pharmaceutical and biotechnology companies where she led multiple discovery and CMC teams of ~25 FTEs. Thanks to her contribution several viral vectored vaccines were successfully designed and developed, including a commercialized Ebola vaccine (Zabdeno) and others which are currently in clinical development for polio, zika, HIV and RSV. Barbara completed a PhD in molecular virology at the University of Amsterdam and is an inventor of eight patents. Frank S Walsh, PhD – Independent Board Member Frank is an accomplished pharmaceutical and biotechnology senior executive with over 20 years of experience. He currently serves as the founding CEO of Ossianix. Frank has had a long-term research interest in ALS, where his work initially focused on developing human neuronal cell culture models and on the role of autoimmunity. His current work is determining the role of the neurotrophin receptor TrkB on motor neuron survival. As head of Discovery Research worldwide at Wyeth Pharmaceuticals in Collegeville, PA he studied myostatin and neutralizing antibodies in the SOD-1 ALS mouse model. Prior to joining Wyeth, he was SVP at GlaxoSmithKline UK and Head of the Neurology CEDD and VP of Neuroscience Research at Smith Kline Beecham UK. Before joining the pharmaceutical industry, Frank had a distinguished academic career in Neuroscience as the Sir William Dunn Professor of Experimental Pathology at London’s UMDS, Guy’s Hospital. Frank has served on the research committee of the Motor Neuron Disease Association in the UK and was Chairman of the ALSA Ice Bucket Challenge drug discovery initiative. Currently, he is a member of the Scientific Advisory Board at Target ALS, New York and the Packard Center, Johns Hopkins University, Baltimore. He received his PhD from University College London and has authored over 200 scientific publications. He is a Fellow of the Royal Society of Edinburgh and the UK Academy of Medical Sciences and has honorary degrees from the University of Perugia and Bologna, Italy and Dundee and Strathclyde, UK. About VectorY VectorY combines the therapeutic potential of antibodies and gene therapy to develop long-lasting therapeutic solutions for neurodegenerative diseases with high unmet medical need such as Amyotrophic Lateral Sclerosis (ALS) and Huntington’s disease. VectorY is a fully integrated gene therapy company focused on the development of innovative therapeutics based on a novel AAV gene therapy platform, antibody-based targeted protein degradation technologies and proprietary manufacturing technology. While focusing initially on neurodegenerative diseases, VectorY's synergistic technologies may be applied across a wide range of indications. VectorY was founded in October 2020 and is based on the Amsterdam Science Park. For more information, see . View source version on businesswire.com: Contacts VectorY Therapeutics B.V. Sariette Witte, Head of Communications E-mail: sariette.witte@vectorytx.com Tel: +31 681 174 072 Instinctif Partners (media enquiries) Melanie Toyne-Sewell / Giulia Lasagni / Manisha Kuttetira E-mail: VectorY@instinctif.com Tel: +44 20 7457 2020 Source: VectorY View this news release online at:

Just weeks after a J&J candidate failed its first trial in an effort to build a vaccine against HIV, that same vaccine technology scored the company a victory in the fight against a virus that has emerged yet again, and threatens to cause havoc in Africa if left unchecked alongside Covid-19. A two-dose vaccine regimen from J&J to fight Ebola was long-lasting during trials in adults and children, the company said Monday , as the immune response lasts in adults for at least two years. The regimen — which uses Zabdeno (Ad26.ZEBOV) for one shot, and Mvabea (MVA-BN-Filo) for the next, 56 days later — spurred no safety concerns, and J&J said that a booster shot could be administered two years after the initial vaccination, as it showed a strong immune response seven days later. Vaccination against Ebola is welcomed: The virus has killed about half of the people it infects. The World Health Organization has put West Africa on notice, as new outbreaks have put pressure on African healthcare systems that are often already working with limited resources. “These peer-reviewed data support the prophylactic use of the Johnson & Johnson Ebola vaccine regimen to protect people at risk of Ebola, which is essential to our vision of preventing Ebola outbreaks before they can begin,” J&J CSO Paul Stoffels said in a statement. “Recent and ongoing outbreaks in Africa underscore that the threat of Ebola is not going away, which is why we collaborated to develop a vaccine regimen capable of inducing long-term immunity against Ebola and are now working to ensure that it is accessible to people in need.” Zabdeno is created on an adenovirus-based platform that genetically modifies those viruses to prevent them from replicating in humans as they ferry immunity-inducing glycoproteins into the body, while Mvabea is delivered on a modified Ankara vector. Because children account for a large portion of Ebola cases and deaths, a randomized, double-blinded trial in Sierra Leone, a region heavily affected by the 2014-2016 West African Ebola outbreak that was the worst on record to date, J&J said, was conducted in healthy children between the ages of 1 and 17. They were split up into three cohorts — ages 1-3, 4-11 and 12-17 — and there were 192 children in each group. As far as side effects are concerned, the most common was injection site pain, the Lancet paper said . The company said that there were no treatment-related deaths, and the antibody response 21 days after the second dose was observed in 98% of children. The vaccine regimen was approved in Europe in July 2020, and received prequalification from the WHO in April 2021, which allows it to be used in developing countries. Earlier this year, outbreaks in Sierra Leone and Guinea caused J&J to announce the donation of 200,000 doses of the jab.